These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11222884)

  • 1. Single-dose toxicity study of hepatic intra-arterial infusion of doxorubicin coupled to a novel magnetically targeted drug carrier.
    Goodwin SC; Bittner CA; Peterson CL; Wong G
    Toxicol Sci; 2001 Mar; 60(1):177-83. PubMed ID: 11222884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers.
    Leakakos T; Ji C; Lawson G; Peterson C; Goodwin S
    Cancer Chemother Pharmacol; 2003 Jun; 51(6):445-50. PubMed ID: 12802508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adsorption and desorption of chemotherapeutic drugs from a magnetically targeted carrier (MTC).
    Rudge S; Peterson C; Vessely C; Koda J; Stevens S; Catterall L
    J Control Release; 2001 Jul; 74(1-3):335-40. PubMed ID: 11489515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of doxorubicin alginate microspheres and evaluation of its hepatic arterial embolization in vivo].
    Liu D; Wang PC; Qi XR; Zou Q; Zou YH; Hong H
    Yao Xue Xue Bao; 2006 Aug; 41(8):778-83. PubMed ID: 17039787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-eluting beads for liver embolization: concentration of doxorubicin in tissue and in beads in a pig model.
    Namur J; Wassef M; Millot JM; Lewis AL; Manfait M; Laurent A
    J Vasc Interv Radiol; 2010 Feb; 21(2):259-67. PubMed ID: 20123210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of hepatobiliary disposition of doxorubicin following intrahepatic delivery of different dosage forms.
    Lilienberg E; Ebeling Barbier C; Nyman R; Hedeland M; Bondesson U; Axén N; Lennernäs H
    Mol Pharm; 2014 Jan; 11(1):131-44. PubMed ID: 24171458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Transhepatic arterial embolization with superparamagnetic iron oxide and lipiodol for the treatment of VX2 tumor in rabbits].
    Liang Q; Deng L; Feng Z; Liu X; Ding J; Hu P; Wang W
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Nov; 42(11):1248-1256. PubMed ID: 29187650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of hepatic extraction and clearance of doxorubicin.
    August DA; Verma N; Vaertan MA; Shah R; Brenner DE
    Br J Cancer; 1995 Jul; 72(1):65-71. PubMed ID: 7599068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vivo Anticancer Efficacy and Toxicity Studies of a Novel Polymer Conjugate N-Acetyl Glucosamine (NAG)-PEG-Doxorubicin for Targeted Cancer Therapy.
    Pawar S; Mahajan K; Vavia P
    AAPS PharmSciTech; 2017 Nov; 18(8):3021-3033. PubMed ID: 28497240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent.
    Hopewel JW; Duncan R; Wilding D; Chakrabarti K
    Hum Exp Toxicol; 2001 Sep; 20(9):461-70. PubMed ID: 11776408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcatheter intra-arterial infusion of doxorubicin loaded porous magnetic nano-clusters with iodinated oil for the treatment of liver cancer.
    Jeon MJ; Gordon AC; Larson AC; Chung JW; Kim YI; Kim DH
    Biomaterials; 2016 May; 88():25-33. PubMed ID: 26938029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/ conventional angiography suite--initial experience with four patients.
    Wilson MW; Kerlan RK; Fidelman NA; Venook AP; LaBerge JM; Koda J; Gordon RL
    Radiology; 2004 Jan; 230(1):287-93. PubMed ID: 14695402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane.
    Della Torre P; Mazué G; Podestà A; Moneta D; Sammartini U; Imondi AR
    Cancer Chemother Pharmacol; 1999; 43(2):151-6. PubMed ID: 9923821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fullerenol nanoparticles prevents doxorubicin-induced acute hepatotoxicity in rats.
    Jacevic V; Djordjevic A; Srdjenovic B; Milic-Tores V; Segrt Z; Dragojevic-Simic V; Kuca K
    Exp Mol Pathol; 2017 Apr; 102(2):360-369. PubMed ID: 28315688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-targeted intracellular delivery of anticancer drugs through the mannose-6-phosphate/insulin-like growth factor II receptor.
    Prakash J; Beljaars L; Harapanahalli AK; Zeinstra-Smith M; de Jager-Krikken A; Hessing M; Steen H; Poelstra K
    Int J Cancer; 2010 Apr; 126(8):1966-1981. PubMed ID: 19795464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional pharmacokinetics of doxorubicin following hepatic arterial and portal venous administration: evaluation with hepatic venous isolation and charcoal hemoperfusion.
    Iwasaki T; Ku Y; Kusunoki N; Tominaga M; Fukumoto T; Muramatsu S; Kuroda Y
    Cancer Res; 1998 Aug; 58(15):3339-43. PubMed ID: 9699664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
    Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
    Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slow infusion rate of doxorubicin induces higher pro-inflammatory cytokine production.
    Tien CC; Peng YC; Yang FL; Subeq YM; Lee RP
    Regul Toxicol Pharmacol; 2016 Nov; 81():69-76. PubMed ID: 27494949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic arterial infusion of verapamil and doxorubicin with complete hepatic venous isolation and extracorporeal chemofiltration: pharmacological evaluation of reduction in systemic drug exposure and assessment of hepatic toxicity.
    Fuhrman GM; Cromeens DM; Newman RA; Cleary KR; Carrasco CH; Wright KC; Guercio S; Guercio A; Curley SA
    Surg Oncol; 1994 Feb; 3(1):17-25. PubMed ID: 8186867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.